The purpose of this Notice of Funding Opportunity (NOFO) is to promote research studies designed to address adverse sequelae of cancer therapies that persist and become chronic co-morbidities or develop as delayed posttreatment effects. This NOFO supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, and translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. The scope of research projects includes mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
- About
- Administration
- Research Programs
- Clinical Research
- Shared Resources
-
Training & Education
- Middle & High School Programs
- Summer Undergraduate Research Programs
- Post-baccalaureate: STAR-PREP
- Graduate Training & Education
- Predoctoral T32 Training Program in Cancer Biology
- Postdoctoral T32 Training Program in Cancer Biology
- Postdoctoral Training
- Clinical Residency / Fellowship
- American Cancer Society Institutional Research Grants
- Continuing Medical Education
- Radiation Therapy Training Program
- Steering Committee
- T32 Cancer Biology Training Grant
- Community Outreach
- Funding Opportunities
- Events Calendar
- Newsroom
- Member Resources
Breadcrumb
Filters
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Organization
NIH
Type
NIH
Link
Number
PAR-25-145
Comments
LOI due 30 days prior to the application due date
Brief Description